Guadalupe Gutierrez

Guadalupe Gutierrez

Auto-generated profile, based on publicly available information

Guadalupe Gutierrez

Pfizer, Inc , New York, New York

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2019 in Physical Biology
Verified
Journal Article
Open access
PDF file
YSYutong Sha
Yutong Sha
DHDaniel Haensel
Daniel Haensel
GGGuadalupe Gutierrez
Guadalupe Gutierrez
HDHuijing Du
Huijing Du
XDXing Dai
Xing Dai
QNQing Nie
Qing Nie
The transition of epithelial cells into a mesenchymal state (epithelial-to-mesenchymal transition or EMT) is a highly dynamic process implicated in various biological processes. During EMT, cells do not necessarily exist in 'pure' epithelial or mesenchymal states. There are cells with mixed (or hybrid) features of the two, which are termed as the intermediate cell states (ICSs). While the exact functions of ICS remain elusive, together with EMT it appears to play important roles in embryogenesis, tissue development, and pathological processes such as cancer metastasis. Recent single cell experiments and advanced mathematical modeling have improved our capability in identifying ICS and provided a better understanding of ICS in development and disease. Here, we review the recent findings related to the ICS in/or EMT and highlight the challenges in the identification and functional characterization of ICS.

1 October 2020 in Cell Reports
Verified
Journal Article
Open access
NPNicholas Pervolarakis
Nicholas Pervolarakis
QNQuy H. Nguyen
Quy H. Nguyen
JWJustice Williams
Justice Williams
YGYanwen Gong
Yanwen Gong
GGGuadalupe Gutierrez
Guadalupe Gutierrez
KKKai Kessenbrock
Kai Kessenbrock
The mammary epithelial cell (MEC) system is a bilayered ductal epithelium of luminal and basal cells, maintained by a lineage of stem and progenitor populations. Here, we used integrated single-cell transcriptomics and chromatin accessibility analysis to reconstruct the cell types of the mouse MEC system and their underlying gene regulatory features in an unbiased manner. We define differentiation states within the secretory type of luminal cells, which forms a continuous spectrum of general luminal progenitor and lactation-committed progenitor cells. By integrating single-cell transcriptomics and chromatin accessibility landscapes, we identify cis- and trans-regulatory elements that are differentially activated in the specific epithelial cell types and our newly defined luminal differentiation states. Our work provides a resource to reveal cis/trans-regulatory elements associated with MEC identity and differentiation that will serve as a reference to determine how the chromatin accessibility landscape changes during breast cancer.

14 December 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PSPeng Sun
Peng Sun
RVRemy Vu
Remy Vu
MDMorgan Dragan
Morgan Dragan
DHDaniel Haensel
Daniel Haensel
GGGuadalupe Gutierrez
Guadalupe Gutierrez
XDXing Dai
Xing Dai

24 August 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
RMRebecca C. Mazahreh
Rebecca C. Mazahreh
CLChuan Bian Lim
Chuan Bian Lim
NGNicolas H. Garcia
Nicolas H. Garcia
DODevra J. Olson
Devra J. Olson
RLRyan Lyski
Ryan Lyski
VTVivian H. Trang
Vivian H. Trang
Integrins represent a large family of cell surface receptors that exist as heterodimers with essential roles in key biological processes such as cellular adhesion, motility, and cytokinesis. Among them, integrin beta-6 (IB6), which exclusively dimerizes with integrin alpha-v, has emerged as a clinically relevant target due to its restricted expression in normal adult epithelial tissues and elevated levels in solid tumors. High expression of IB6 is correlated with poor prognosis across multiple solid tumor types. PF-08046876 is an investigational antibody–drug conjugate consisting of the anti-IB6 mAb conjugated to a camptothecin-class topoisomerase I (TOP1) inhibitor, 7-aminomethyl-10,11-methylenedioxycamptothecin (AMDCPT), using a traceless enzyme-cleavable glucuronide linker. The AMDCPT payload has been optimized for differentiation from other TOP1 inhibitors, with improved potency, enhanced bystander activity, and reduced susceptibility to multidrug resistance efflux mechanisms. PF-08046876 leverages the same antibody backbone from sigvotatug vedotin and binds IB6 without cross-reactivity to other alpha-v integrin complexes. In preclinical studies, PF-08046876 has demonstrated significant antitumor activity both in vitro and in vivo across multiple tumor models with IB6 expression, including non–small cell lung, head and neck squamous cell, urothelial, pancreatic, and esophageal carcinomas. These findings support further clinical development of PF-08046876 as a promising therapeutic candidate for the treatment of IB6-expressing solid tumors.

1 July 2014 in European Journal of Cancer
Verified
Journal Article
Closed access
TCT. Ni Chonghaile
T. Ni Chonghaile
JRJ. Roderick
J. Roderick
GGG. Gutierrez
G. Gutierrez
MKM. Kelliher
M. Kelliher
ALA. Letai
A. Letai

17 September 2023 in ISEE Conference Abstracts
Verified
Journal Article
Open access
MPMaria Politis
Maria Politis
MYMeizhen Yao
Meizhen Yao
CGChris Gennings
Chris Gennings
MTMarcela Tamayo-Ortiz
Marcela Tamayo-Ortiz
CAChitra Amarasiriwardena
Chitra Amarasiriwardena
Maria Jose RosaMaria Jose Rosa
Maria Jose Rosa